Mitsubishi UFJ Trust & Banking
RPRX icon

Mitsubishi UFJ Trust & Banking’s Royalty Pharma RPRX Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.3M Sell
1,307,514
-186,961
-13% -$9.73M 0.16% 129
2026
Q1 		$71.7M Sell
1,494,475
-269,794
-15% -$11.8M 0.18% 125
2025
Q4 		$68.2M Buy
1,764,269
+245,570
+16% +$9.36M 0.16% 131
2025
Q3 		$53.6M Sell
1,518,699
-198,889
-12% -$7.2M 0.12% 188
2025
Q2 		$61.9M Sell
1,717,588
-19,650
-1% -$651K 0.14% 163
2025
Q1 		$54.1M Sell
1,737,238
-131,904
-7% -$4.18M 0.14% 159
2024
Q4 		$47.7M Sell
1,869,142
-137,164
-7% -$3.64M 0.11% 197
2024
Q3 		$56.8M Buy
2,006,306
+175,439
+10% +$4.86M 0.13% 162
2024
Q2 		$48.3M Sell
1,830,867
-26,131
-1% -$724K 0.12% 195
2024
Q1 		$56.4M Buy
1,856,998
+175,261
+10% +$5.17M 0.13% 182
2023
Q4 		$47.2M Sell
1,681,737
-147,146
-8% -$4.04M 0.11% 209
2023
Q3 		$49.6M Buy
1,828,883
+301,651
+20% +$8.96M 0.12% 184
2023
Q2 		$46.9M Sell
1,527,232
-61,633
-4% -$2.09M 0.11% 204
2023
Q1 		$57.2M Buy
1,588,865
+94,736
+6% +$3.51M 0.14% 166
2022
Q4 		$59M Sell
1,494,129
-69,390
-4% -$2.9M 0.15% 156
2022
Q3 		$62.8M Buy
1,563,519
+263,669
+20% +$11.3M 0.18% 135
2022
Q2 		$54.6M Buy
1,299,850
+1,124,071
+639% +$46.1M 0.14% 162
2022
Q1 		$6.85M Sell
175,779
-4,710
-3% -$185K 0.02% 649
2021
Q4 		$7.19M Buy
180,489
+70,746
+64% +$2.75M 0.01% 671
2021
Q3 		$3.96M Buy
109,743
+5,466
+5% +$212K 0.01% 773
2021
Q2 		$4.29M Sell
104,277
-3,408
-3% -$145K 0.01% 770
2021
Q1 		$4.74M Buy
107,685
+26,128
+32% +$1.24M 0.01% 726
2020
Q4 		$4.08M Buy
+81,557
New +$3.46M 0.01% 754

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's RPRX Position: Q2 2026 in Review

Mitsubishi UFJ Trust & Banking reduced its Royalty Pharma (RPRX) stake by 13% in Q2 2026, selling an estimated $9.73M and leaving 1,307,514 shares worth $73.3M. The position accounts for 0.16% of the portfolio, ranked #129.

Mitsubishi UFJ Trust & Banking first reported a position in RPRX in Q4 2020 and has held it in 23 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Mitsubishi UFJ Trust & Banking held 1,307,514 shares of Royalty Pharma worth $73.3M as of Q2 2026.
  • Mitsubishi UFJ Trust & Banking sold 186,961 Royalty Pharma shares in Q2 2026, an estimated $9.73M.
  • Royalty Pharma made up 0.16% of Mitsubishi UFJ Trust & Banking's portfolio in Q2 2026, its #129 holding.
  • Mitsubishi UFJ Trust & Banking first reported a position in Royalty Pharma in Q4 2020 and has held it in 23 quarters since.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q2 2026, filed 6 Aug 2026.